- Conditions
- Major Depressive Disorder
- Interventions
- GLYX-13 5 mg/kg, GLYX-13 10 mg/kg, Placebo
- Drug
- Lead sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Encino, California • Los Alamitos, California + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 1,859
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Coronary Disease
- Interventions
- INS50589 Intravenous Infusion
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 160 participants
- Timeline
- Started 2006
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • San Diego, California • Springfield, Illinois + 13 more
- Conditions
- Hypoglycemia
- Interventions
- Exendin (9-39), Placebo
- Drug · Other
- Lead sponsor
- Tracey McLaughlin
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab, Olaparib, Placebo for olaparib, Etoposide, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Thoracic Radiotherapy, Durvalumab
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 33
- States / cities
- Mobile, Alabama • Jonesboro, Arkansas • Fullerton, California + 28 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- teplizumab, Placebo
- Biological
- Lead sponsor
- Provention Bio, Inc.
- Industry
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 34
- States / cities
- San Diego, California • San Francisco, California • Walnut Creek, California + 30 more
- Conditions
- Community-acquired Pneumonia, Bacterial Pneumonia
- Interventions
- CMTX-101, Placebo
- Drug
- Lead sponsor
- Clarametyx Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 8
- States / cities
- Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Abatacept, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 19
- States / cities
- Huntsville, Alabama • Palm Desert, California • Palo Alto, California + 16 more
- Conditions
- Healthy
- Interventions
- ABL301, Placebo
- Drug
- Lead sponsor
- ABL Bio, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Acute Kidney Injury
- Interventions
- Suramin, Placebo
- Drug
- Lead sponsor
- Rediscovery Life Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • La Mesa, California • Los Angeles, California + 9 more
- Conditions
- Tobacco Smoking
- Interventions
- Ketamine, Midazolam, Dexmedetomidine, Saline
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Postpartum Depression
- Interventions
- Placebo, SAGE-547 90 μg/kg/h
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 32
- States / cities
- Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 28 more
- Conditions
- Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
- Interventions
- Tarlatamab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 13 more
- Conditions
- Healthy Volunteers
- Interventions
- Danavorexton, Danavorexton Placebo, Propofol, Sevoflurane
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Radiocontrast Nephropathy
- Interventions
- N-Acetylcysteine (NAC), 0.9% Sodium-chloride
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 399 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- High-risk Smoldering Multiple Myeloma
- Interventions
- Siltuximab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Rockville, Maryland • Detroit, Michigan + 5 more
- Conditions
- Atherosclerosis
- Interventions
- LS followed by NS diet condition, NS followed by LS diet condition, Placebo, RO6836191
- Other · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Marlton, New Jersey
- Conditions
- Acute Kidney Injury (AKI)
- Interventions
- ASP1128, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 27
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Clearwater, Florida + 23 more
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- thrombomodulin alfa, Placebo
- Drug
- Lead sponsor
- Veloxis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 18
- States / cities
- Beverly Hills, California • Los Angeles, California • Norwich, Connecticut + 15 more
- Conditions
- Healthy
- Interventions
- NAV-240, Placebo
- Drug
- Lead sponsor
- Navigator Medicines, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Anti-CD20 (rituximab), Placebo Comparator
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 8 Years to 45 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 10 more
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis
- Interventions
- PF-06835375, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 17
- States / cities
- Anniston, Alabama • Beverly Hills, California • Los Angeles, California + 9 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more
- Conditions
- Pompe Disease (Late-onset)
- Interventions
- Cipaglucosidase Alfa, Miglustat, Alglucosidase Alfa, Placebo
- Biological · Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Irvine, California + 21 more
- Conditions
- Colitis, Ulcerative
- Interventions
- Placebo, Golimumab 1 mg per kg, Golimumab 2 mg per kg, Golimumab 4 mg per kg
- Other · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 36
- States / cities
- Orange, California • Roseville, California • Littleton, Colorado + 33 more